Related references
Note: Only part of the references are listed.Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Discovery of 6-(2,4-Dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid (SAR439859), a Potent and Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen-Receptor-Positive Breast Cancer
Youssef El-Ahmad et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Self-assembled single-atom nanozyme for enhanced photodynamic therapy treatment of tumor
Dongdong Wang et al.
NATURE COMMUNICATIONS (2020)
Overcoming Endocrine Resistance in Breast Cancer
Ariella B. Hanker et al.
CANCER CELL (2020)
SynergyFinder 2.0: visual analytics of multi-drug combination synergies
Aleksandr Ianevski et al.
NUCLEIC ACIDS RESEARCH (2020)
Gambogic Acid as a Candidate for Cancer Therapy: A Review
Yuling Liu et al.
INTERNATIONAL JOURNAL OF NANOMEDICINE (2020)
Targeting CDK4/6 pathways and beyond in breast cancer
Domen Ribnikar et al.
BREAST (2019)
Ligand-binding Domain-activating Mutations of ESR1 Rewire Cellular Metabolism of Breast Cancer Cells
Lotem Zinger et al.
CLINICAL CANCER RESEARCH (2019)
Breast Cancer Treatment A Review
Adrienne G. Waks et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER plus breast cancer
Luigi Formisano et al.
NATURE COMMUNICATIONS (2019)
Ca2+ signalling plays a role in celastrol-mediated suppression of synovial fibroblasts of rheumatoid arthritis patients and experimental arthritis in rats
Vincent Kam Wai Wong et al.
BRITISH JOURNAL OF PHARMACOLOGY (2019)
Advances in Endocrine-Based Therapies for Estrogen Receptor-Positive Metastatic Breast Cancer
Vassilis Aggelis et al.
DRUGS (2019)
Naturally occurring anti-cancer compounds: shining from Chinese herbal medicine
Hua Luo et al.
CHINESE MEDICINE (2019)
A high-throughput drug combination screen of targeted small molecule inhibitors in cancer cell lines
Asmund Flobak et al.
SCIENTIFIC DATA (2019)
Synthesis of novel guttiferone E and xanthochymol derivatives with cytotoxicities by inducing cell apoptosis and arresting the cell cycle phase
Xin Lin et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)
Next-Generation ERα Inhibitors for Endocrine-Resistant ER+ Breast Cancer
Sean W. Fanning et al.
ENDOCRINOLOGY (2019)
Allele-Specific Chromatin Recruitment and Therapeutic Vulnerabilities of ESR1 Activating Mutations
Rinath Jeselsohn et al.
CANCER CELL (2018)
Therapeutic potential of gambogic acid, a caged xanthone, to target cancer
Kishore Banik et al.
CANCER LETTERS (2018)
Abstract PD5-10: A first-in-human phase I study to evaluate the oral selective estrogen receptor degrader (SERD), GDC-0927, in postmenopausal women with estrogen receptor positive (ER+) HER2-negative metastatic breast cancer (BC)
MN Dickler et al.
CANCER RESEARCH (2018)
Pharmacological inhibition of dihydroorotate dehydrogenase induces apoptosis and differentiation in acute myeloid leukemia cells
Dang Wu et al.
HAEMATOLOGICA (2018)
Discovery of LSZ102, a Potent, Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen Receptor Positive Breast Cancer
George S. Tria et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Proteomic profiling identifies key coactivators utilized by mutant ER alpha proteins as potential new therapeutic targets
Leah A. Gates et al.
ONCOGENE (2018)
Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment
Hitisha K. Patel et al.
PHARMACOLOGY & THERAPEUTICS (2018)
Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ERαWT and ERαMUT Breast Cancer
Xiaoling Puyang et al.
CANCER DISCOVERY (2018)
Pharmacological inhibition of dihydroorotate dehydrogenase induces apoptosis and differentiation in acute myeloid leukemia cells
Dang Wu et al.
HAEMATOLOGICA (2018)
The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers
Pedram Razavi et al.
CANCER CELL (2018)
The Y537S ESR1 mutation is a dominant driver of distant ER-positive breast cancer metastasis
Guowei Gu et al.
CANCER RESEARCH (2018)
Activating ESR1 Mutations Differentially Affect the Efficacy of ER Antagonists
Weiyi Toy et al.
CANCER DISCOVERY (2017)
Selective targeting p53WT lung cancer cells harboring homozygous p53 Arg72 by an inhibitor of CypA
W. Lu et al.
ONCOGENE (2017)
The RNA-Binding Site of Poliovirus 3C Protein Doubles as a Phosphoinositide-Binding Domain
Djoshkun Shengjuler et al.
STRUCTURE (2017)
Elacestrant (RAD1901), a Selective Estrogen Receptor Degrader (SERD), Has Antitumor Activity in Multiple ER+ Breast Cancer Patient-derived Xenograft Models
Teeru Bihani et al.
CLINICAL CANCER RESEARCH (2017)
Effects of G1T48, a novel orally bioavailable selective estrogen receptor degrader (SERD), and the CDK4/6 inhibitor, G1T38, on tumor growth in animal models of endocrine resistant breast cancer
Suzanne E. Wardell et al.
CANCER RESEARCH (2017)
Estrogen Receptor a Promotes Breast Cancer by Reprogramming Choline Metabolism
Min Jia et al.
CANCER RESEARCH (2016)
AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and ESR1-Mutant Breast Tumors in Preclinical Models
Hazel M. Weir et al.
CANCER RESEARCH (2016)
Alternative to the soft-agar assay that permits high-throughput drug and genetic screens for cellular transformation
Asaf Rotem et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Mechanisms of aromatase inhibitor resistance
Cynthia X. Ma et al.
NATURE REVIEWS CANCER (2015)
Emergence of Constitutively Active Estrogen Receptor-α Mutations in Pretreated Advanced Estrogen Receptor-Positive Breast Cancer
Rinath Jeselsohn et al.
CLINICAL CANCER RESEARCH (2014)
D538G Mutation in Estrogen Receptor-α: A Novel Mechanism for Acquired Endocrine Resistance in Breast Cancer
Keren Merenbakh-Lamin et al.
CANCER RESEARCH (2013)
ESR1 ligand-binding domain mutations in hormone-resistant breast cancer
Weiyi Toy et al.
NATURE GENETICS (2013)
Activating ESR1 mutations in hormone-resistant metastatic breast cancer
Dan R. Robinson et al.
NATURE GENETICS (2013)
Monitoring Drug Target Engagement in Cells and Tissues Using the Cellular Thermal Shift Assay
Daniel Martinez Molina et al.
SCIENCE (2013)
Gaussia princeps Luciferase as a Reporter for Transcriptional Activity, Protein Secretion, and Protein-Protein Interactions in Salmonella enterica Serovar Typhimurium
Thorsten Wille et al.
APPLIED AND ENVIRONMENTAL MICROBIOLOGY (2012)
Discovery of Potent Ligands for Estrogen Receptor β by Structure-Based Virtual Screening
Jie Shen et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
A highly sensitive protein-protein interaction assay based on Gaussia luciferase
Ingrid Remy et al.
NATURE METHODS (2006)
Evaluation of an estrogen receptor-β agonist in animal models of human disease
HA Harris et al.
ENDOCRINOLOGY (2003)
Investigations on estrogen receptor binding. The estrogenic, antiestrogenic, and cytotoxic properties of C2-alkyl-substituted 1,1-bis(4-hydroxyphenyl)-2-phenylethenes
V Lubczyk et al.
JOURNAL OF MEDICINAL CHEMISTRY (2002)
Prediction of estrogen receptor binding for 58,000 chemicals using an integrated system of a tree-based model with structural alerts
HX Hong et al.
ENVIRONMENTAL HEALTH PERSPECTIVES (2002)
Share Paper
